It’s being expected that by 2028, the Pharmaceutical Contract Manufacturing market cap will hit USD 175.79 Billion at a CAGR growth of about 7%.
The rising demand for biologics and generic medicines and capital-intensive environment of the industry, and composite manufacturing requirements, various pharmaceutical companies have recognized the potential productivity in contracting with a contract manufacturing outsourcing for both commercial and clinical stage manufacturing.
The main objective of this market report is to deliver detailed information of the global pharmaceutical contract manufacturing market. The report also covers the present and future trends, key players, detailed analysis of the geographical segmentation in terms of both volume and value of the global pharmaceutical contract manufacturing market.
Geographically, Europe and North America are projected to represent the largest global pharmaceutical contract manufacturing market share in terms of revenue. The growth of these counties is augmented by the high application of biologics and growing aged population. The increasing demand for generics and growing research activities by biotechnology industries are some global pharmaceutical contract manufacturing market trends. The United States will be a main revenue sponsor in the North America market. Asia Pacific region is anticipated to develop as a profitable market over the forecast period due to the rising government initiatives and developing healthcare infrastructure.
The global pharmaceutical contract manufacturing market is segmented on the basis of product, application, end-user, and region. Based on product, this market is segmented as API, FDF, Nutritional products, advanced drug delivery, and others. By application, the market is classified as Biopharmaceutical and pharmaceutical. Based on end-user, the market segmented as sterile and non-sterile. By region, this market is categorized into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Here is the list of top 10 pharmaceutical contract manufacturing companies which are popular for their wide range, quality products, and affordable prices:
Top 10 pharmaceutical contract manufacturing companies
- Patheon
- Catalent
- Boehringer Ingelheim
- Lonza
- PCI
- Almac
- Vetter
- Famar
- Dr. Reddy’s Laboratories
- Recipharm
Key players of global pharmaceutical contract manufacturing market
- Recipharm AB
- Catalent Inc.
- Patheon Inc.
- Jubilant Life Sciences Ltd.
- Pfizer Centresource
- Boehringer Ingelheim
- Aenova
- Baxter Biopharma Solutions
- Famer
- Lonza
- Others
Pharmaceutical Contract Manufacturing Market Scope
Metrics | Details |
Base Year | 2020 |
Historic Data | 2018-2019 |
Forecast Period | 2021-2028 |
Study Period | 2018-2028 |
Forecast Unit | Value (USD) |
Revenue forecast in 2028 | USD 175.79 Billion |
Growth Rate | CAGR of 7 % during 2021-2028 |
Segment Covered | Type, Regions |
Regions Covered | North America, Europe, Asia Pacific, Middle East and Africa, South America |
Key Players Profiled | Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GMBH (Germany), FAMAR Health Care Services (Greece), AbbVie Inc. (US), Aenova Group (Germany), Consort Medical plc (UK), Almac Group (UK), Siegfried Holding AG (Switzerland), Boehringer Ingelheim International GmbH (Germany), and Evonik Industries AG (Germany). |
Segmentation of global pharmaceutical contract manufacturing market:
By Product
- API (Active Pharmaceutical Ingredients)
- FDF (Finished Dosage Formulations)
- Capsule
- Tablet
- Injectable/Parenteral
- Oral Liquids
- Others
- Nutritional Products and OTC Medicines
- Advanced Drug Delivery Products
- Others
By Application
- Biopharmaceutical
- Pharmaceutical
By End-user
- Sterile
- Non-sterile
By Region
- North America
- Canada
- United States
- Europe
- France
- Germany
- U.K.
- Spain
- Switzerland
- Italy
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Rest of APAC
- Latin America
- Middle East and Africa